FDA Grants Fast Track Designation to ACR-368 in Platinum-resistant Ovarian Cancer and Endometrial Cancer
The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.
Acrivon Oncosignature Peter Blume Jensen International Federation Of Gynecology Acrivon Therapeutic Oncosignature Fast Track Checkpoint Kinase
Source: onclive.com